Cargando…

Combination Therapies for HPV-Associated Malignancies

Human papillomavirus (HPV)-associated malignancies cause almost all cases of cervical cancer in women, and a significant percentage of head and neck cancer, together totaling almost 5% of the global cancer burden, and representing an important public health issue. The approval and use of two prophyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smalley Rumfiled, Claire, Schlom, Jeffrey, Jochems, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276916/ https://www.ncbi.nlm.nih.gov/pubmed/34262794

Ejemplares similares

Therapeutic Vaccines for HPV-Associated Malignancies
por: Smalley Rumfield, Claire, et al.
Publicado: (2020)

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
por: Smalley Rumfield, Claire, et al.
Publicado: (2020)

Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
por: Pellom, Samuel T., et al.
Publicado: (2021)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

Combination therapies utilizing neoepitope-targeted vaccines
por: Lee, Karin L., et al.
Publicado: (2020)

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
por: Jochems, Caroline, et al.
Publicado: (2018)

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
por: Lee, Maxwell Y., et al.
Publicado: (2021)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis
por: Gilbert, Duncan C., et al.
Publicado: (2018)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Reply to Comments on “Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis”
por: Gilbert, Duncan C., et al.
Publicado: (2019)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies
por: Inan, Hakan, et al.
Publicado: (2017)

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
por: Kowalczyk, Joshua T, et al.
Publicado: (2022)

The use of monoclonal antibody B72.3 in the management of gynecologic malignancies.
por: Simpson, J., et al.
Publicado: (1988)

Malignancy Associated with Low-Risk HPV6 and HPV11: A Systematic Review and Implications for Cancer Prevention
por: da Silva, Leandro Lima, et al.
Publicado: (2023)

Malignant Transformation of Temporal Bone Schneiderian Papilloma Associated with HPV-6
por: Marzouk, O., et al.
Publicado: (2021)

Monoclonal antibodies in cervical malignancy-related HPV
por: Aghbash, Parisa Shiri, et al.
Publicado: (2022)

Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer
por: Malamas, Anthony S., et al.
Publicado: (2017)

Effects of conventional therapeutic interventions on the number and function of regulatory T cells
por: Roselli, Mario, et al.
Publicado: (2013)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
por: Lui, Grace, et al.
Publicado: (2023)

Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer
por: Scholten, Kirsten BJ, et al.
Publicado: (2011)

Comment on “Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis”
por: Jayaraj, Rama, et al.
Publicado: (2019)

Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis"
por: Péré, Hélène, et al.
Publicado: (2019)

Lack of HPV in Benign and Malignant Epithelial Ovarian Tumors in Iran
por: Farzaneh, Farah, et al.
Publicado: (2017)

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells
por: Donahue, Renee N, et al.
Publicado: (2013)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
por: Gatti-Mays, Margaret E., et al.
Publicado: (2021)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy?
por: Đukić, Anamaria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5tqescuu65obat10hejbc2mnk0